Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
| Autor: | Balar, Arjun V *, Kamat, Ashish M, Kulkarni, Girish S, Uchio, Edward M, Boormans, Joost L, Roumiguié, Mathieu, Krieger, Laurence E M, Singer, Eric A, Bajorin, Dean F, Grivas, Petros, Seo, Ho Kyung, Nishiyama, Hiroyuki, Konety, Badrinath R, Li, Haojie, Nam, Kijoeng, Kapadia, Ekta, Frenkl, Tara, de Wit, Ronald |
|---|---|
| Zdroj: | In The Lancet Oncology July 2021 22(7):919-930 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|